Stem Cell Therapy Alternatives for Type 1 Diabetes: Current Progress and Limitations
DOI:
https://doi.org/10.58445/35scek68Keywords:
stem cells, Type 1 Diabetes, current treatments, diabetes treatment strategiesAbstract
Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease that causes a lack of insulin production by the pancreas. In the USA alone, there are around 2.1 million people affected by this condition. Patients must manage their blood sugar levels due to the lack of insulin. The standard treatment for this condition is lifelong insulin therapy. However, insulin pumps do not replace the beta cells that produce insulin and can cause problems with exercise, cost, and managing treatment. Due to this, research into stem cell therapies is being investigated. This review looks at the efficacy and safety of cell-based therapies that have been used in clinical studies for treating T1DM, including stem cell-derived islet cells and mesenchymal stem cells.
References
American Diabetes Association. (n.d.-a). The cost of access to diabetes technologies. https://diabetes.org/tools-resources/managing-diabetes-costs/cost-access-diabetes-technologies
American Diabetes Association. (n.d.-b). Severe hypoglycemia (severe low blood glucose). https://diabetes.org/living-with-diabetes/hypoglycemia-low-blood-glucose/severe
American Diabetes Association Professional Practice Committee for Diabetes. (2026). 6. Glycemic goals, hypoglycemia, and hyperglycemic crises: Standards of care in diabetes—2026. Diabetes Care, 49(Supplement 1), S132–S149. https://doi.org/10.2337/dc26-S006
Baxter, F., Baillie, N., Dover, A., Stimson, R. H., Gibb, F., & Forbes, S. (2024). A cross-sectional questionnaire study: Impaired awareness of hypoglycaemia remains prevalent in adults with type 1 diabetes and is associated with the risk of severe hypoglycaemia. PLOS ONE, 19(6), e0297601. https://doi.org/10.1371/journal.pone.0297601
Centers for Disease Control and Prevention. (2026, September 16). National diabetes statistics report. https://www.cdc.gov/diabetes/php/data-research/index.html
Cleveland Clinic. (2022a, October 3). C-peptide test. https://my.clevelandclinic.org/health/diagnostics/24242-c-peptide-test
Cleveland Clinic. (2022b, June 9). Neutropenia: What it is, types, symptoms & causes. https://my.clevelandclinic.org/health/diseases/21058-neutropenia
Cleveland Clinic. (2023, December 11). Insulin pumps. https://my.clevelandclinic.org/health/articles/insulin-pumps
Cleveland Clinic. (2024a, February 6). Brittle diabetes: What it is, causes, symptoms & treatment. https://my.clevelandclinic.org/health/diseases/21499-brittle-diabetes
Cleveland Clinic. (2024b, February 29). Type 1 vs. type 2 diabetes: What’s the difference? https://health.clevelandclinic.org/type-1-vs-type-2-diabetes
Cleveland Clinic. (2025a, March 24). Allogeneic stem cell transplant. https://my.clevelandclinic.org/health/treatments/22790-allogeneic-stem-cell-transplantation
Cleveland Clinic. (2025b, November 21). Diabetes-related ketoacidosis (DKA): Symptoms & treatment. https://my.clevelandclinic.org/health/diseases/21945-diabetic-ketoacidosis-dka
Cleveland Clinic. (2026, August 12). Type 1 diabetes: What it is, symptoms, causes & treatment. https://my.clevelandclinic.org/health/diseases/21500-type-1-diabetes
Dana-Farber Staff. (2019, November 11). Autologous vs. allogeneic stem cell transplants: What’s the difference? Dana-Farber Cancer Institute. https://blog.dana-farber.org/insight/2017/03/autologous-vs-allogenic-stem-cell-transplants-whats-the-difference/
Foster, E. D., Bridges, N. D., Feurer, I. D., Eggerman, T. L., Hunsicker, L. G., Alejandro, R., & Clinical Islet Transplantation Consortium. (2018). Improved health-related quality of life in a phase 3 islet transplantation trial in type 1 diabetes complicated by severe hypoglycemia. Diabetes Care, 41(5), 1001–1008. https://doi.org/10.2337/dc17-1779
Gillespie, C. (2025, March 6). What is brittle diabetes? HealthCentral. https://www.healthcentral.com/condition/type-1-diabetes/brittle-diabetes
Grattoni, A., Korbutt, G., Tomei, A. A., García, A. J., Pepper, A. R., Stabler, C., Brehm, M., Papas, K., Citro, A., Shirwan, H., Millman, J. R., Melero-Martin, J., Graham, M., Sefton, M., Ma, M., Kenyon, N., Veiseh, O., Desai, T. A., Nostro, M. C., ... Sykes, M. (2025). Harnessing cellular therapeutics for type 1 diabetes mellitus: Progress, challenges, and the road ahead. Nature Reviews Endocrinology, 21(1), 14–30. https://doi.org/10.1038/s41574-024-01029-0
Hering, B. J., Clarke, W. R., Bridges, N. D., Eggerman, T. L., Alejandro, R., Bellin, M. D., Chaloner, K., Czarniecki, C. W., Goldstein, J. S., Hunsicker, L. G., Kaufman, D. B., Korsgren, O., Larsen, C. P., Luo, X., Markmann, J. F., Naji, A., Oberholzer, J., Posselt, A. M., Rickels, M. R., Ricordi, C., … Clinical Islet Transplantation Consortium. (2016). Phase 3 trial of transplantation of human islets in type 1 diabetes complicated by severe hypoglycemia. Diabetes Care, 39(7), 1230–1240. https://doi.org/10.2337/dc15-1988
Labcorp. (n.d.). C-peptide. https://www.labcorp.com/tests/010108/c-peptide
Lu, J., Shen, S. M., Ling, Q., Wang, B., Li, L. R., Zhang, W., Qu, D. D., Bi, Y., & Zhu, D. L. (2021). One repeated transplantation of allogeneic umbilical cord mesenchymal stromal cells in type 1 diabetes: an open parallel controlled clinical study. Stem Cell Research & Therapy, 12(1), 340. https://doi.org/10.1186/s13287-021-02417-3
Mayo Clinic. (2026, January 21). Stem cells: What they are and what they do. https://www.mayoclinic.org/tests-procedures/bone-marrow-transplant/in-depth/stem-cells/art-20048117
McNeilly, A. D., & McCrimmon, R. J. (2018). Impaired hypoglycaemia awareness in type 1 diabetes: lessons from the lab. Diabetologia, 61(4), 743–750. https://doi.org/10.1007/s00125-018-4548-8
Mousaei Ghasroldasht, M., Seok, J., Park, H. S., Liakath Ali, F. B., & Al-Hendy, A. (2022). Stem cell therapy: From idea to clinical practice. International Journal of Molecular Sciences, 23(5), 2850. https://doi.org/10.3390/ijms23052850
National Cancer Institute. (2023, October 5). Stem cell transplants in cancer treatment. https://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant
National Library of Medicine. (n.d.-a). Diabetes type 2. MedlinePlus. https://medlineplus.gov/diabetestype2.html
National Library of Medicine. (n.d.-b). Hemoglobin A1C (HbA1c) test. MedlinePlus. https://medlineplus.gov/lab-tests/hemoglobin-a1c-hba1c-test/
Opałka, B., Żołnierczuk, M., & Grabowska, M. (2023). Immunosuppressive agents—effects on the cardiovascular system and selected metabolic aspects: A review. Journal of Clinical Medicine, 12(21), 6935. https://doi.org/10.3390/jcm12216935
Perkins, B. A., & Riddell, M. C. (2006). Type 1 diabetes and exercise: Using the insulin pump to maximum advantage. Canadian Journal of Diabetes, 30(1), 72–79. https://doi.org/10.1016/S1499-2671(06)01008-2
Ramphul, K., & Joynauth, J. (2020). An update on the incidence and burden of diabetic ketoacidosis in the U.S. Diabetes Care, 43(12), e196–e197. https://doi.org/10.2337/dc20-1258
Reichman, T. W., Markmann, J. F., Odorico, J., Witkowski, P., Fung, J. J., Wijkstrom, M., Kandeel, F., de Koning, E. J. P., Peters, A. L., Mathieu, C., Kean, L. S., Bruinsma, B. G., Wang, C., Mascia, M., Sanna, B., Marigowda, G., Pagliuca, F., Melton, D., Ricordi, C., & Rickels, M. R. (2025). Stem cell-derived, fully differentiated islets for type 1 diabetes. The New England Journal of Medicine, 393(9), 858–868. https://doi.org/10.1056/NEJMoa2506549
Rios, P., McGarrigle, J. J., Lamonica, G., Li, Y., Cook, J., Joshi, I., Ghani, S., Cook, D., Lopez, D., Nasir, H., Wang, Y., & Oberholzer, J. (2024). 35-OR: Lantidra, first FDA-approved cellular therapy to treat type 1 diabetes. Diabetes, 73(Supplement 1), 35-OR. https://doi.org/10.2337/db24-35-OR
Sneddon, J. B., Tang, Q., Stock, P., Bluestone, J. A., Roy, S., Desai, T., & Hebrok, M. (2018). Stem cell therapies for treating diabetes: Progress and remaining challenges. Cell Stem Cell, 22(6), 810–823. https://doi.org/10.1016/j.stem.2018.05.016
U.S. Food and Drug Administration. (2023, June 28). FDA approves first cellular therapy to treat patients with type 1 diabetes. https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-treat-patients-type-1-diabetes
Vinay, E. S., Rao, B. L. N., Saf, N., & Gautam, D. (2026). C-peptide in precision diabetes care and beyond: A comprehensive review. Clinical Medicine Insights: Endocrinology and Diabetes, 19, 11795514251397811. https://doi.org/10.1177/11795514251397811
Wan, X. X., Zhang, D. Y., Khan, M. A., Zheng, S. Y., Hu, X. M., Zhang, Q., Yang, R. H., & Xiong, K. (2022). Stem Cell Transplantation in the Treatment of Type 1 Diabetes Mellitus: From Insulin Replacement to Beta-Cell Replacement. Frontiers in Endocrinology, 13, 859638. https://doi.org/10.3389/fendo.2022.859638
Wang, S., Du, Y., Zhang, B., Meng, G., Liu, Z., Liew, S. Y., Liang, R., Zhang, Z., Cai, X., Wu, S., Gao, W., Zhuang, D., Zou, J., Huang, H., Wang, M., Wang, X., Wang, X., Liang, T., Liu, T., . . . Shen, Z. (2024). Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient. Cell, 187(22), 6152–6164.e18. https://doi.org/10.1016/j.cell.2024.09.004
Zuo, D. B., Wang, C. H., Sang, M., Sun, X. D., Chen, G. P., & Ji, K. K. (2025). Stem cell therapy for diabetes: Advances, prospects, and challenges. World Journal of Diabetes, 16(7), 107344. https://doi.org/10.4239/wjd.v16.i7.107344
Downloads
Posted
Categories
License
Copyright (c) 2026 Research Archive of Rising Scholars

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.